Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00046267 · ClinicalTrials.gov registry record · NA

Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients

A NA study of HIV Infections and Diabetes Mellitus, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
NA
Development phase
30
Enrollment target
16
Study locations

NCT00046267 is a NA study of HIV Infections and Diabetes Mellitus that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 30 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (93% lower). The trial reports 16 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00046267, a NA study of HIV Infections and Diabetes Mellitus, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
16
Study locations

Study Summary

The purpose of this study is to evaluate the safety, efficacy, and tolerability of extended-release niacin (Niaspan) in improving the level of fats in the blood of HIV-infected patients.

Conditions Studied

HIV Infections Diabetes Mellitus Hypercholesterolemia Hypertriglyceridemia

Interventions

  • DRUG Niacin

Study Locations (16)

California

  • UCLA School of Medicine - Los Angeles
  • Univ of California, San Diego Antirviral Research - San Diego
  • San Mateo County AIDS Program - Stanford
  • Stanford Univ - Stanford
  • Willow Clinic - Stanford

Indiana

  • Indiana University Hospital - Indianapolis
  • Methodist Hosp of Indiana - Indianapolis
  • Wishard Hospital - Indianapolis

Missouri

  • St. Louis Connect Care - St Louis
  • Washington Univ (St. Louis) - St Louis

Ohio

  • Univ of Cincinnati - Cincinnati
  • Case Western Reserve Univ - Cleveland

Colorado

  • Univ of Colorado Health Sciences Ctr, Denver - Denver

Florida

  • Univ of Miami School of Medicine - Miami

Minnesota

  • Univ of Minnesota - Minneapolis

Pennsylvania

  • Univ of Pittsburgh - Pittsburgh

Trial Details

FieldValue
Enrollment Target 30 participants
Phase NA

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00046267

The ClinicalTrials.gov registry entry for NCT00046267 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (93% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Niacin is the first listed.

NCT00046267 reports 16 study locations spanning 8 distinct geographic areas - top geographies include California, Indiana, Missouri.

Frequently Asked Questions

What is clinical trial NCT00046267 about?

NCT00046267 is a clinical study titled "Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients". The purpose of this study is to evaluate the safety, efficacy, and tolerability of extended-release niacin (Niaspan) in improving the level of fats in the blood of HIV-infected patients.

What is the current status of trial NCT00046267?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants.

What conditions does trial NCT00046267 study?

This clinical trial studies the following conditions: HIV Infections, Diabetes Mellitus, Hypercholesterolemia, Hypertriglyceridemia.

What interventions are being tested in trial NCT00046267?

The interventions under investigation include: Niacin (DRUG).

Who is sponsoring clinical trial NCT00046267?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00046267 being conducted?

This trial has 16 study locations across California, Colorado, Florida, Indiana, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

Diabetes Mellitus

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.